These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 36547945)

  • 1. Tissue-Based PD-L1 Expression Is the Strongest Predictor of Overall Survival Benefit From ICI in Advanced Gastroesophageal Cancer-Reply.
    Yoon HH; Shi Q; Ajani JA
    JAMA Oncol; 2023 Feb; 9(2):280-281. PubMed ID: 36547945
    [No Abstract]   [Full Text] [Related]  

  • 2. Association of PD-L1 Expression and Other Variables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal Cancer: Systematic Review and Meta-analysis of 17 Phase 3 Randomized Clinical Trials.
    Yoon HH; Jin Z; Kour O; Kankeu Fonkoua LA; Shitara K; Gibson MK; Prokop LJ; Moehler M; Kang YK; Shi Q; Ajani JA
    JAMA Oncol; 2022 Oct; 8(10):1456-1465. PubMed ID: 36006624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of PD-1/PD-L1 inhibitors in advanced gastroesophageal cancer based on characteristics: a meta-analysis.
    Liu W; Huo G; Chen P
    Immunotherapy; 2023 Jul; 15(10):751-771. PubMed ID: 37190983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low Programmed Death-Ligand 1-Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma.
    Zhao JJ; Yap DWT; Chan YH; Tan BKJ; Teo CB; Syn NL; Smyth EC; Soon YY; Sundar R
    J Clin Oncol; 2022 Feb; 40(4):392-402. PubMed ID: 34860570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue-Based PD-L1 Expression Is the Strongest Predictor of Overall Survival Benefit From ICI in Advanced Gastroesophageal Cancer.
    Zhang X; Ning C; Zhao H
    JAMA Oncol; 2023 Feb; 9(2):280. PubMed ID: 36547972
    [No Abstract]   [Full Text] [Related]  

  • 6. Beyond the PD-L1 horizon: In search for a good biomarker to predict success of immunotherapy in gastric and esophageal adenocarcinoma.
    Koemans WJ; Chalabi M; van Sandick JW; van Dieren JM; Kodach LL
    Cancer Lett; 2019 Feb; 442():279-286. PubMed ID: 30419350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of PD-1/PD-L1 inhibitors in gastric or gastro-oesophageal junction cancer based on clinical characteristics: a meta-analysis.
    Huo G; Liu W; Chen P
    BMC Cancer; 2023 Feb; 23(1):143. PubMed ID: 36765356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. All in the Levels-Programmed Death-Ligand 1 Expression as a Biomarker for Immune Checkpoint Inhibitor Response in Patients with Gastrointestinal Cancer.
    Das S; Cimino S; Davis S; Ciombor K
    Oncologist; 2021 Jan; 26(1):e186-e188. PubMed ID: 32945067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy for Esophageal and Gastric Cancer.
    Kelly RJ
    Am Soc Clin Oncol Educ Book; 2017; 37():292-300. PubMed ID: 28561677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of anti-PD-1/PD-L1 agents vs chemotherapy in patients with gastric or gastroesophageal junction cancer: a systematic review and meta-analysis.
    Wang BC; Zhang ZJ; Fu C; Wang C
    Medicine (Baltimore); 2019 Nov; 98(47):e18054. PubMed ID: 31764833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer.
    Greally M; Chou JF; Chatila WK; Margolis M; Capanu M; Hechtman JF; Tuvy Y; Kundra R; Daian F; Ladanyi M; Kelsen DP; Ilson DH; Berger MF; Tang LH; Solit DB; Diaz LA; Schultz N; Janjigian YY; Ku GY
    Clin Cancer Res; 2019 Oct; 25(20):6160-6169. PubMed ID: 31337644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastric cancer mesenchymal stem cells regulate PD-L1-CTCF enhancing cancer stem cell-like properties and tumorigenesis.
    Sun L; Huang C; Zhu M; Guo S; Gao Q; Wang Q; Chen B; Li R; Zhao Y; Wang M; Chen Z; Shen B; Zhu W
    Theranostics; 2020; 10(26):11950-11962. PubMed ID: 33204322
    [No Abstract]   [Full Text] [Related]  

  • 13. An investigation of the clinical impact and therapeutic relevance of a DNA damage immune response (DDIR) signature in patients with advanced gastroesophageal adenocarcinoma.
    Baxter MA; Spender LC; Cairns D; Walsh S; Oparka R; Porter RJ; Bray S; Skinner G; King S; Turbitt J; Collinson D; Miedzybrodzka ZH; Jellema G; Logan G; Kennedy RD; Turkington RC; McLean MH; Swinson D; Grabsch HI; Lord S; Seymour MJ; Hall PS; Petty RD
    ESMO Open; 2024 May; 9(5):103450. PubMed ID: 38744099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Programmed cell death 1 as prognostic marker and therapeutic target in upper gastrointestinal cancers.
    Khoshghamat N; Jafari N; Moetamani-Ahmadi M; Khalili-Tanha G; Khajavi Rad MH; Sahebdel S; Khalili-Tanha N; Soleimanpour S; Khazaei M; Hassanian SM; Ferns GA; Avan A
    Pathol Res Pract; 2021 Apr; 220():153390. PubMed ID: 33640713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1.
    Fashoyin-Aje L; Donoghue M; Chen H; He K; Veeraraghavan J; Goldberg KB; Keegan P; McKee AE; Pazdur R
    Oncologist; 2019 Jan; 24(1):103-109. PubMed ID: 30120163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-1 inhibitors in esophageal cancer: a systematic review of the oncological outcomes associated with PD-1 blockade and the evolving therapeutic paradigm.
    Whooley J; Alazzawi M; Donlon NE; Bolger JC; Robb WB
    Dis Esophagus; 2022 May; 35(5):. PubMed ID: 34553222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress and prospects of immune checkpoint inhibitors in advanced gastric cancer.
    Zeng Z; Yang B; Liao Z
    Future Oncol; 2021 Apr; 17(12):1553-1569. PubMed ID: 33397136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers.
    Van Der Kraak L; Goel G; Ramanan K; Kaltenmeier C; Zhang L; Normolle DP; Freeman GJ; Tang D; Nason KS; Davison JM; Luketich JD; Dhupar R; Lotze MT
    J Immunother Cancer; 2016; 4():65. PubMed ID: 27777774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune microenvironment characteristics and their implications for immune checkpoint inhibitor efficacy in HER2-overexpressing gastric cancer.
    Cen S; Xu H; Liu Z; Zhao R; Pan H; Han W
    Clin Exp Immunol; 2022 May; 207(3):318-328. PubMed ID: 35553632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-L1 polymorphisms predict survival outcomes in advanced non-small-cell lung cancer patients treated with PD-1 blockade.
    Yoshida H; Nomizo T; Ozasa H; Tsuji T; Funazo T; Yasuda Y; Ajimizu H; Yamazoe M; Kuninaga K; Ogimoto T; Hosoya K; Itotani R; Sakamori Y; Kim YH; Hirai T
    Eur J Cancer; 2021 Feb; 144():317-325. PubMed ID: 33385948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.